TrialHistopathology2019

Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.

Paul Barrow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.